<p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）的股票在目前覆盖该公司的十三家评级机构中获得了 “适度买入” 的平均推荐，MarketBeat.com 报道称。一位分析师对该股票给予了卖出评级，两位给予了持有评级，十位则对该公司给予了买入评级。在过去一年中，更新了对该股票覆盖的分析师的平均一年价格目标为 48.9167 美元。</p>
<ul>
<li>3 家不为人知的医疗保健公司</li>
</ul>
<p>一些股票研究分析师最近对 TVTX 股票发布了报告。TD Cowen 将 Travere Therapeutics 的股票目标价从 45.00 美元上调至 60.00 美元，并在 5 月 5 日的研究报告中给予该公司 “买入” 评级。Wedbush 在 6 月 3 日的研究报告中重申了 “跑赢大盘” 评级，并对 Travere Therapeutics 的股票设定了 55.00 美元的目标价。花旗集团在周三将 Travere Therapeutics 的股票目标价从 59.00 美元上调至 62.00 美元，并给予该公司 “买入” 评级。Piper Sandler 在 4 月 14 日的研究报告中将 Travere Therapeutics 的股票评级从 “中性” 上调至 “增持”，并设定了 49.00 美元的目标价。最后，HC Wainwright 在 6 月 2 日的研究报告中将 Travere Therapeutics 的股票目标价从 57.00 美元上调至 67.00 美元，并给予该公司 “买入” 评级。</p>
<p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们关于 TVTX 的最新报告</strong></p>
<h2>内部人士下注</h2>
<ul>
<li>Travere Therapeutics 在鼓舞人心的数据后仍在上升</li>
</ul>
<p>在其他新闻中，首席执行官 Eric M. Dube 在 5 月 6 日的交易中出售了 22,500 股公司的股票。这些股票以平均价格 43.95 美元出售，总价值为 988,875.00 美元。出售后，首席执行官直接持有 432,886 股公司的股票，价值约为 19,025,339.70 美元。此次交易使其持股减少了 4.94%。该交易已在与证券交易委员会的法律文件中披露，文件可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 William E. Rote 在 5 月 6 日的交易中出售了 2,763 股公司的股票。这些股票以平均价格 43.95 美元出售，总交易额为 121,433.85 美元。出售完成后，该内部人士直接持有 115,474 股公司的股票，价值为 5,075,082.30 美元。这笔交易代表其持股减少了 2.34%。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士出售了价值 15,895,428 美元的 400,015 股公司股票。内部人士持有公司股票的 4.44%。</p>
<h2>机构投资者对 Travere Therapeutics 的看法</h2>
<p>几家大型投资者最近增加或减少了对该公司的持股。加利福尼亚州教师退休系统在第一季度将其在 Travere Therapeutics 的持股增加了 32.3%。加利福尼亚州教师退休系统现在拥有 105,132 股公司股票，价值 3,123,000 美元，在此期间又购买了 25,660 股。Elmind Capital LP 在第一季度将其在 Travere Therapeutics 的持股增加了 61.5%。Elmind Capital LP 现在拥有 177,600 股公司股票，价值 5,276,000 美元，在此期间又购买了 67,600 股。Empowered Funds LLC 在第一季度将其在 Travere Therapeutics 的持股增加了 2,719.8%。Empowered Funds LLC 现在拥有 84,820 股公司股票，价值 2,520,000 美元，在此期间又购买了 81,812 股。Quantinno Capital Management LP 在第一季度将其在 Travere Therapeutics 的持股增加了 354.4%。Quantinno Capital Management LP 现在拥有 68,317 股公司股票，价值 2,030,000 美元，在此期间又购买了 53,283 股。最后，Rice Hall James &amp; Associates LLC 在第一季度将其在 Travere Therapeutics 的持股增加了 1.3%。Rice Hall James &amp; Associates LLC 现在拥有 92,757 股公司股票，价值 2,756,000 美元，在此期间又购买了 1,221 股。</p>
<h2>Travere Therapeutics 股票表现</h2>
<p>纳斯达克：TVTX 周一开盘价为 45.81 美元。该公司的债务与股本比率为 3.16，流动比率为 3.13，速动比率为 3.08。该公司的市值为 42.6 亿美元，市盈率为-199.17，贝塔值为 1.13。该公司的 50 日移动平均线为 39.71 美元，200 日移动平均线为 34.79 美元。Travere Therapeutics 的 1 年最低价为 13.88 美元，1 年最高价为 48.61 美元。</p>
<p>Travere Therapeutics（纳斯达克代码：TVTX - 获取免费报告）最后一次发布季度财报是在 5 月 4 日。该公司报告每股收益（EPS）为 0.05 美元，超出分析师的共识预期（-0.24 美元）0.29 美元。该公司本季度的收入为 1.272 亿美元，而共识预期为 1.3623 亿美元。Travere Therapeutics 的净利润率为-4.00%，股本回报率为-26.16%。该公司的收入同比增长 55.6%。在去年同期，该公司每股收益为-0.47 美元。分析师预测 Travere Therapeutics 在本年度将发布-0.29 美元的每股收益。</p>
<h2>关于 Travere Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Travere Therapeutics, Inc NASDAQ: TVTX 是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的疗法。公司的使命是通过关注影响小患者群体的疾病，解决治疗选择有限的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
<p>公司的主要产品是 sparsentan，一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Travere Therapeutics</li>
<li>这三只保险股创下 52 周新高：还有买入的机会吗？</li>
<li>三只股价低于 20 美元的股票，值得在更广泛的市场反弹前买入</li>
<li>Petco 面临激烈竞争，但势头正在增强</li>
<li>锁定效应是真实存在的——这三家房屋建筑商正在押注于此</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Travere Therapeutics 吗？</h2>
<p>在考虑 Travere Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在买入的股票，而 Travere Therapeutics 并不在名单上。</p>
<p>虽然 Travere Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

TVTX

<p>Travere Therapeutics（纳斯达克代码：TVTX）获得了 13 位分析师的 “适度买入” 共识，1 年期平均目标价为 48.92 美元。最近的升级包括 TD Cowen 将其目标价上调至 60 美元，花旗集团上调至 62 美元。同时，首席执行官 Eric M. Dube 和内部人士 William E. Rote 在 5 月份根据 10b5-1 规则出售了股份。相反，包括加利福尼亚州教师退休系统和 Elmind Capital LP 在内的几家机构投资者在第一季度显著增加了他们的持股</p>

<p>Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have received an average recommendation of &#34;Moderate Buy&#34; from the thirteen ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $48.9167.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）的股票在目前覆盖该公司的十三家评级机构中获得了 “适度买入” 的平均推荐，MarketBeat.com 报道称。一位分析师对该股票给予了卖出评级，两位给予了持有评级，十位则对该公司给予了买入评级。在过去一年中，更新了对该股票覆盖的分析师的平均一年价格目标为 48.9167 美元。</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不为人知的医疗保健公司</li>
</ul>
</div><p>A number of equities research analysts have recently issued reports on TVTX shares. TD Cowen boosted their price target on shares of Travere Therapeutics from $45.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, May 5th. Wedbush reissued an &#34;outperform&#34; rating and issued a $55.00 price target on shares of Travere Therapeutics in a research note on Wednesday, June 3rd. Citigroup boosted their price target on shares of Travere Therapeutics from $59.00 to $62.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday. Piper Sandler raised shares of Travere Therapeutics from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and set a $49.00 price target on the stock in a research note on Tuesday, April 14th. Finally, HC Wainwright boosted their price target on shares of Travere Therapeutics from $57.00 to $67.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, June 2nd.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 TVTX 股票发布了报告。TD Cowen 将 Travere Therapeutics 的股票目标价从 45.00 美元上调至 60.00 美元，并在 5 月 5 日的研究报告中给予该公司 “买入” 评级。Wedbush 在 6 月 3 日的研究报告中重申了 “跑赢大盘” 评级，并对 Travere Therapeutics 的股票设定了 55.00 美元的目标价。花旗集团在周三将 Travere Therapeutics 的股票目标价从 59.00 美元上调至 62.00 美元，并给予该公司 “买入” 评级。Piper Sandler 在 4 月 14 日的研究报告中将 Travere Therapeutics 的股票评级从 “中性” 上调至 “增持”，并设定了 49.00 美元的目标价。最后，HC Wainwright 在 6 月 2 日的研究报告中将 Travere Therapeutics 的股票目标价从 57.00 美元上调至 67.00 美元，并给予该公司 “买入” 评级。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Report on TVTX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TVTX 的最新报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的数据后仍在上升</li>
</ul>
</div><p>In other news, CEO Eric M. Dube sold 22,500 shares of the business's stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total value of $988,875.00. Following the sale, the chief executive officer directly owned 432,886 shares of the company's stock, valued at approximately $19,025,339.70. The trade was a 4.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William E. Rote sold 2,763 shares of the business's stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $121,433.85. Following the completion of the sale, the insider directly owned 115,474 shares in the company, valued at $5,075,082.30. This trade represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 400,015 shares of company stock worth $15,895,428. Insiders own 4.44% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Eric M. Dube 在 5 月 6 日的交易中出售了 22,500 股公司的股票。这些股票以平均价格 43.95 美元出售，总价值为 988,875.00 美元。出售后，首席执行官直接持有 432,886 股公司的股票，价值约为 19,025,339.70 美元。此次交易使其持股减少了 4.94%。该交易已在与证券交易委员会的法律文件中披露，文件可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 William E. Rote 在 5 月 6 日的交易中出售了 2,763 股公司的股票。这些股票以平均价格 43.95 美元出售，总交易额为 121,433.85 美元。出售完成后，该内部人士直接持有 115,474 股公司的股票，价值为 5,075,082.30 美元。这笔交易代表其持股减少了 2.34%。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士出售了价值 15,895,428 美元的 400,015 股公司股票。内部人士持有公司股票的 4.44%。</p>
</div><h2>Institutional Investors Weigh In On Travere Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Travere Therapeutics 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its stake in Travere Therapeutics by 32.3% during the 1st quarter. California State Teachers Retirement System now owns 105,132 shares of the company's stock worth $3,123,000 after buying an additional 25,660 shares during the period. Elmind Capital LP increased its stake in Travere Therapeutics by 61.5% during the 1st quarter. Elmind Capital LP now owns 177,600 shares of the company's stock worth $5,276,000 after buying an additional 67,600 shares during the period. Empowered Funds LLC increased its stake in Travere Therapeutics by 2,719.8% during the 1st quarter. Empowered Funds LLC now owns 84,820 shares of the company's stock worth $2,520,000 after buying an additional 81,812 shares during the period. Quantinno Capital Management LP increased its stake in Travere Therapeutics by 354.4% during the 1st quarter. Quantinno Capital Management LP now owns 68,317 shares of the company's stock worth $2,030,000 after buying an additional 53,283 shares during the period. Finally, Rice Hall James &amp; Associates LLC increased its stake in Travere Therapeutics by 1.3% during the 1st quarter. Rice Hall James &amp; Associates LLC now owns 92,757 shares of the company's stock worth $2,756,000 after buying an additional 1,221 shares during the period.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对该公司的持股。加利福尼亚州教师退休系统在第一季度将其在 Travere Therapeutics 的持股增加了 32.3%。加利福尼亚州教师退休系统现在拥有 105,132 股公司股票，价值 3,123,000 美元，在此期间又购买了 25,660 股。Elmind Capital LP 在第一季度将其在 Travere Therapeutics 的持股增加了 61.5%。Elmind Capital LP 现在拥有 177,600 股公司股票，价值 5,276,000 美元，在此期间又购买了 67,600 股。Empowered Funds LLC 在第一季度将其在 Travere Therapeutics 的持股增加了 2,719.8%。Empowered Funds LLC 现在拥有 84,820 股公司股票，价值 2,520,000 美元，在此期间又购买了 81,812 股。Quantinno Capital Management LP 在第一季度将其在 Travere Therapeutics 的持股增加了 354.4%。Quantinno Capital Management LP 现在拥有 68,317 股公司股票，价值 2,030,000 美元，在此期间又购买了 53,283 股。最后，Rice Hall James &amp; Associates LLC 在第一季度将其在 Travere Therapeutics 的持股增加了 1.3%。Rice Hall James &amp; Associates LLC 现在拥有 92,757 股公司股票，价值 2,756,000 美元，在此期间又购买了 1,221 股。</p>
</div><h2>Travere Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Travere Therapeutics 股票表现</h2>
</div><p>NASDAQ:TVTX opened at $45.81 on Monday. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 3.08. The firm has a market capitalization of $4.26 billion, a price-to-earnings ratio of -199.17 and a beta of 1.13. The company's 50-day moving average is $39.71 and its two-hundred day moving average is $34.79. Travere Therapeutics has a 1-year low of $13.88 and a 1-year high of $48.61.</p>
<div class="lb-trans"><p>纳斯达克：TVTX 周一开盘价为 45.81 美元。该公司的债务与股本比率为 3.16，流动比率为 3.13，速动比率为 3.08。该公司的市值为 42.6 亿美元，市盈率为-199.17，贝塔值为 1.13。该公司的 50 日移动平均线为 39.71 美元，200 日移动平均线为 34.79 美元。Travere Therapeutics 的 1 年最低价为 13.88 美元，1 年最高价为 48.61 美元。</p>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million for the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business's revenue was up 55.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.47) EPS. Analysts forecast that Travere Therapeutics will post -0.29 EPS for the current year.</p>
<div class="lb-trans"><p>Travere Therapeutics（纳斯达克代码：TVTX - 获取免费报告）最后一次发布季度财报是在 5 月 4 日。该公司报告每股收益（EPS）为 0.05 美元，超出分析师的共识预期（-0.24 美元）0.29 美元。该公司本季度的收入为 1.272 亿美元，而共识预期为 1.3623 亿美元。Travere Therapeutics 的净利润率为-4.00%，股本回报率为-26.16%。该公司的收入同比增长 55.6%。在去年同期，该公司每股收益为-0.47 美元。分析师预测 Travere Therapeutics 在本年度将发布-0.29 美元的每股收益。</p>
</div><h2>About Travere Therapeutics</h2>
<div class="lb-trans"><h2>关于 Travere Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc NASDAQ: TVTX 是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的疗法。公司的使命是通过关注影响小患者群体的疾病，解决治疗选择有限的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>公司的主要产品是 sparsentan，一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?</li>
<li>3 Stocks Under $20 to Buy Before a Broader Market Rally</li>
<li>Petco Faces Tough Competition, But Momentum Is Building</li>
<li>The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Travere Therapeutics</li>
<li>这三只保险股创下 52 周新高：还有买入的机会吗？</li>
<li>三只股价低于 20 美元的股票，值得在更广泛的市场反弹前买入</li>
<li>Petco 面临激烈竞争，但势头正在增强</li>
<li>锁定效应是真实存在的——这三家房屋建筑商正在押注于此</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Travere Therapeutics 吗？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Travere Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在买入的股票，而 Travere Therapeutics 并不在名单上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Travere Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Beat

Travere Therapeutics, Inc.（纳斯达克股票代码：TVTX）被券商一致评为 “适度买入”